创新药板块“王者归来”的戏码仍在上演。作为创新药企“卖水人”的CRO板块，也开始触底反弹。据统计显示，截至最新收盘，东方财富的CRO指数年内涨幅已超过了49%，在一众概念指数中位居前列，而CRO相关概念股的表现则更加突出，例如CRO“一哥”药明康德，年内股价上涨近100%。相比之下，被视为行业第二、仅次于药明康德的康龙化成，表现就稍微差一些。截至最新收盘，康龙化成年内涨幅仅22.75%，其涨幅不但...
Source Link创新药板块“王者归来”的戏码仍在上演。作为创新药企“卖水人”的CRO板块，也开始触底反弹。据统计显示，截至最新收盘，东方财富的CRO指数年内涨幅已超过了49%，在一众概念指数中位居前列，而CRO相关概念股的表现则更加突出，例如CRO“一哥”药明康德，年内股价上涨近100%。相比之下，被视为行业第二、仅次于药明康德的康龙化成，表现就稍微差一些。截至最新收盘，康龙化成年内涨幅仅22.75%，其涨幅不但...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.